Syros Pharmaceuticals said Tuesday that it has hired Jorge Conde as chief financial officer and chief product officer. Previously, Conde was the co-founder and CFO of Knome. Based in Watertown, Mass., Syros is focused on treating cancer and other diseases. It is backed by Flagship Ventures and ARCH Venture Partners.
WATERTOWN, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals, a therapeutics company harnessing breakthroughs in gene control to discover and develop revolutionary drugs to treat cancer and other diseases, announced today that Jorge Conde has joined Syros’ executive leadership team as its Chief Financial Officer (CFO) and Chief Product Officer. Mr. Conde will lead the platform strategy for Syros’ novel gene regulation technology and manage the overall finances for the company.
Prior to joining Syros, Mr. Conde co-founded Knome with George Church, Professor of Genetics at Harvard Medical School, based on genomic technologies developed in Professor Church’s laboratory. Mr. Conde was most recently CFO at Knome. He brings to Syros over 15 years of health care experience in strategy, finance and product development. Prior to Knome, Mr. Conde worked in marketing and operations at MedImmune, the global biologics arm of AstraZeneca. He has worked in the life sciences group at Flagship Ventures and managed the business development function at Helicos Biosciences, a next-generation DNA sequencing company. Previously, he was an investment banker at Morgan Stanley where he advised biotechnology and genomics companies on strategy, M&A and capital fundraising.
“The Syros proprietary drug discovery platform generates drugs that target the root causes of disease through unique insights into gene control. This innovative approach leverages proprietary analytics and informatics developed by Syros and its founders. We are excited to have Jorge lead our efforts to maximize the value of this powerful engine,” said Nancy Simonian, M.D., Chief Executive Officer, Syros. “Jorge’s broad experience in life science companies and finance is an ideal fit for Syros.”
“Syros’ groundbreaking science focused on the regulome, the gene control region of the genome, is poised to address the dominant question of the post-genomics era: ‘of the hundreds of thousands of genetic abnormalities identified in people, which ones are important, and why?’ Syros’ platform makes it possible to take a much broader view that has implications not just for therapeutics, but also for how informatics and diagnostics can interplay with them,” said Mr. Conde. “I am thrilled to join this outstanding team of scientists, inventors, executives, and industry leaders to further develop Syros’ cutting-edge technology for the benefit of patients.”
Mr. Conde has been named one of the top 35 young innovators in the world by the MIT Technology Review. He holds an M.B.A. from Harvard Business School, a Master of Science degree from the Harvard-MIT Division of Health Sciences and Technology (HST), and a Bachelor’s degree in Biology from Johns Hopkins University.
About Syros Pharmaceuticals
Syros Pharmaceuticals is a therapeutics company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases. Syros’ proprietary platform identifies the master switches for disease genes, opening a whole new approach to novel therapeutics. Syros’ initial focus is in cancer, but the company platform will also be applicable to other therapeutic areas. The Company’s founders are pioneers in gene control research and translation. Co-founded and backed by Flagship Ventures and ARCH Venture Partners, Syros Pharmaceuticals is located in Watertown, MA. For more information, visit www.syros.com.